Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac

Cancer Research

Volumn 67, Issue 2, 2007, Pages 520-527

  Morrison, Helen ^a,b   Sperka, Tobias ^a,b   Manent, Jan ^c   Giovannini, Marco ^c   Ponta, Helmut ^b   Herrlich, Peter ^a,b  

^a FRITZ LIPMANN INSTITUTE   (Germany)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^c FONDATION JEAN DAUSSET CEPH   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; EZRIN; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR RECEPTOR BINDING PROTEIN 2; MERLIN; MITOGEN ACTIVATED PROTEIN KINASE; MOESIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN P21; PROTEIN TYROSINE KINASE; RAC PROTEIN; RADIXIN; RAS PROTEIN; SOS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYTOSKELETAL PROTEINS; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; NEURILEMMOMA; NEUROFIBROMIN 2; NIH 3T3 CELLS; PLATELET-DERIVED GROWTH FACTOR; RAC GTP-BINDING PROTEINS; RAS PROTEINS; RATS; SON OF SEVENLESS PROTEINS; TRANSFECTION;

EID: 33846702026     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1608     Document Type: Article

References (50)

1. Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 1992;29:841-6.
2. McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev 1997;11:1253-65.
3. McClatchey AI, Saotome I, Mercer K, et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 1998;12:1121-33.
4. Gautreau A, Louvard D, Arpin M. ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr Opin Cell Biol 2002;14:104-9.
5. Legg JW, Isacke CM. Identification and functional analysis of the ezrin-binding site in the hyaluronan receptor, CD44. Curr Biol 1998;8:705-8.
6. 1 integrin associate in isolated and differentiating Schwann cells. J Neurobiol 1998;37:487-501.
7. Tran Quang C, Gautreau A, Arpin M, Treisman R. Ezrin function is required for ROCK-mediated fibroblast transformation by the Net and Dbl oncogenes. EMBO J 2000;19:4565-76.
8. Morrison H, Sherman LS, Legg J, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001;15:968-80.
9. Shaw RJ, Paez JG, Curto M, et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 2001;1:63-72.
10. Gautreau A, Louvard D, Arpin M. Morphogenic effects of ezrin require a phosphorylation-induced transition from oligomers to monomers at the plasma membrane. J Cell Biol 2000;150:193-203.
11. Hirokawa Y, Tikoo A, Huynh J, et al. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J 2004;10:20-6.
12. Tikoo A, Varga M, Ramesh V, Gusella J, Maruta H. An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J Biol Chem 1994;269:23387-90.
13. Kim H, Lim JY, Kim YH, et al. Inhibition of ras-mediated activator protein I activity and cell growth by merlin. Mol Cells 2002;14:108-14.
14. Lim JY, Kim H, Kim YH, et al. Merlin suppresses the SRE-dependent transcription by inhibiting the activation of Ras-ERK pathway. Biochem Biophys Res Commun 2003;302:238-45.
15. Lallemand D, Curto M, Saotome I, Giovannini M, McClatchey AI. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 2003;17:1090-100.
16. Scoles DR, Nguyen VD, Qin Y, et al. Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. Hum Mol Genet 2002;11:3179-89.
17. Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. Merlin, the product of the N12 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell 2003;12:841-9.
18. Fernandez-Valle C, Tang Y, Ricard J, et al. Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet 2002;31:354-62.
19. Medema RH, Wubbolts R, Bos JL. Two dominant inhibitory mutants of p21ras interfere with insulin-induced gene expression. Mol Cell Biol 1991;11:5963-7.
20. Bruder JT, Heidecker G, Rapp UR. Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase. Genes Dev 1992;6:545-56.
21. Mansour SJ, Matten WT, Hermann AS, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994;265:966-70.
22. Nikitin A, Ballering LA, Lyons J, Rajewsky MF. Early mutation of the neu (erbB-2) gene during ethylnitrosourea-induced oncogenesis in the rat Schwann cell lineage. Proc Natl Acad Sci U S A 1991;88:9939-43.
23. Xiao GH, Gallagher R, Shetler J, et al. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 2005;25:2384-94.
24. Claesson-Welsh L. Signal transduction by the PDGF receptors. Prog Growth Factor Res 1994;5:37-54.
25. 1 cell cycle progression independently of p65PAK and the JNK/SAPK MAP kinase cascade. Cell 1996;87:519-29.
26. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002;16:3074-86.
27. Li N, Batzer A, Daly R, et al. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature 1993;363:85-8.
28. Walsh AB, Bar-Sagi D. Differential activation of the Rac pathway by Ha-Ras and K-Ras. J Biol Chem 2001;276:15609-15.
29. Beeser A, Jaffer ZM, Hofmann C, Chernoff J. Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. J Biol Chem 2005;280:36609-15.
30. Li W, Chong H, Guan KL. Function of the Rho family GTPases in Ras-stimulated Raf activation. J Biol Chem 2001;276:34728-37.
31. Tang Y, Yu J, Field J. Signals from the Ras, Rac, and Rho GTPases converge on the Pak protein kinase in Rat-1 fibroblasts. Mol Cell Biol 1999;19:1881-91.
32. Kissil JL, Johnson KC, Eckman MS, Jacks T. Merlin Phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem 2002;277:10394-9.
33. Xiao GH, Beeser A, Chernoff J, Testa JR. p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 2002;277:883-6.
34. Scita G, Nordstrom J, Carbone R, et al. EPS8 and E3B1 transduce signals from Ras to Rac. Nature 1999;401:290-3.
35. Caloca MJ, Zugaza JL, Matallanas D, Crespo P, Bustelo XR. Vav mediates Ras stimulation by direct activation of the GDP/GTP exchange factor Ras GRP1. EMBO J 2003;22:3326-36.
36. Reynolds LF, de Bettignies C, Norton T, Beeser A, Chernoff J, Tybulewicz VL. Vav1 transduces T cell receptor signals to the activation of the Ras/ERK pathway via LAT, Sos, and RasGRP1. J Biol Chem 2004;279:18239-46.
37. Maeda M, Matsui T, Imamura M, Tsukita S. Expression level, subcellular distribution and rho-GDI binding affinity of merlin in comparison with Ezrin/Radixin/Moesin proteins. Oncogene 1999;18:4788-97.
38. Ryu CH, Kim SW, Lee KH, et al. The merlin tumor suppressor interacts with Ral guanine nucleotide dissociation stimulator and inhibits its activity. Oncogene 2005;24:5355-64.
39. Tang Y, Chen Z, Ambrose D, et al. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol Cell Biol 1997;17:4454-64.
40. Slack-Davis JK, Eblen ST, Zecevic M, et al. PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation. J Cell Biol 2003;162:281-91.
41. Frost JA, Steen H, Shapiro P, et al. Cross-cascade activation of ERKs and ternary complex factors by Rho family proteins. EMBO J 1997;16:6426-38.
42. Coles LC, Shaw PE. PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway. Oncogene 2002;21:2236-44.
43. Kallunki T, Deng T, Hibi M, Karin M. c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 1996;87:929-39.
44. Pelton PD, Sherman LS, Rizvi TA, et al. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene 1998;17:2195-209.
45. Wiederhold T, Lee MF, James M, et al. Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2. Oncogene 2004;23:8815-25.
46. Fraenzer JT, Pan H, Minimo L, Jr., Smith GM, Knauer D, Hung G. Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol 2003;23:1493-500.
47. Maitra S, Kulikauskas RM, Gavilan H, Fehon RG. The tumor suppressors Merlin and expanded function cooperatively to modulate receptor endocytosis and signaling. Curr Biol 2006;16:702-9.
48. Jozwiak J. Hamartin and tuberin: working together for tumour suppression. Int J Cancer 2006;118:1-5.
49. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 2001;104:593-604.
50. Sasaki A, Taketomi T, Kato R, et al. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nat Cell Biol 2003;5:427-32.